Simon C Pedder

US Patent:

7829708, Nov 9, 2010

Filed:

Sep 8, 2005

Appl. No.:

11/223433

Inventors:

Michael J. Roberts - Williamsburg VA, US
Simon Pedder - Charlotte NC, US

Assignee:

Chelsea Therapeutics, Inc. - Charlotte NC

International Classification:

C07D 239/72
A61K 31/519

US Classification:

544283, 5142581

Abstract:

The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.

US Patent:

7951812, May 31, 2011

Filed:

Jan 18, 2008

Appl. No.:

12/016528

Inventors:

Michael J. Roberts - Charlotte NC, US
Simon Pedder - Fort Mill SC, US

Assignee:

Chelsea Therapeutics, Inc. - Charlotte NC

International Classification:

C07D 487/04
A61K 31/519
A61P 35/00
A61P 29/00
A61P 11/06
A61P 19/02

US Classification:

5142651, 544278

Abstract:

The present invention is directed to antifolate compounds having the structure.

US Patent:

8008285, Aug 30, 2011

Filed:

Mar 7, 2008

Appl. No.:

12/044680

Inventors:

Michael J. Roberts - Charlotte NC, US
Simon Pedder - Fort Mill SC, US

Assignee:

Chelsea Therapeutics, Inc. - Charlotte NC

International Classification:

A01N 43/40
A01N 37/44
A61K 31/44
A61K 31/195

US Classification:

514183, 514351, 514567

Abstract:

The present invention provides methods of treating fibromyalgia or other diseases or conditions causing widespread pain and/or fatigue. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active agents, that can be used in the inventive methods. The methods of treatment can comprise treating, preventing, reducing, or eliminating a variety of symptoms recognized as indicative of fibromyalgia, such as chronic pain, allodynia, hyperalgesia, fatigue, sleep disturbance, and depression.

US Patent:

8383681, Feb 26, 2013

Filed:

May 7, 2008

Appl. No.:

12/116560

Inventors:

Michael J. Roberts - Charlotte NC, US
Simon Pedder - Fort Mill SC, US

Assignee:

Chelsea Therapeutics, Inc. - Charlotte NC

International Classification:

A61K 31/195
A61K 31/19
A61K 31/135

US Classification:

514567, 514653

Abstract:

The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a compound selected from the group consisting of DOPA decarboxylase inhibiting compounds, catechol-O-methyltransferase inhibiting compounds, cholinesterase inhibiting compounds, monoamine oxidase inhibiting compounds, norepinephrine reuptake inhibiting compounds, selective serotonin reuptake inhibiting compounds, tricyclic antidepressant compounds, serotonin norepinephrine reuptake inhibiting compounds, norepinephrine dopamine reuptake inhibiting compound, noradrenergic and specific serotonergic antidepressants, and combinations thereof. The inventive compositions are particularly useful in the treatment of depression, narcolepsy, insomnia, and Attention Deficit/Hyperactivity Disorder (AD/HD).

US Patent:

20080015181, Jan 17, 2008

Filed:

Jun 28, 2007

Appl. No.:

11/770191

Inventors:

Michael Roberts - Charlotte NC, US
Simon Pedder - Fort Mill SC, US

International Classification:

A61K 31/195
A61K 31/27
A61K 31/407
A61K 31/42
A61K 31/421
A61K 31/435
A61K 31/4353
A61K 31/437
A61K 31/44
A61K 31/4412
A61K 31/5375
A61K 31/55
A61P 9/02

US Classification:

514215000, 514237800, 514292000, 514297000, 514319000, 514351000, 514354000, 514376000, 514378000, 514411000, 514479000, 514490000, 514567000

Abstract:

The present invention provides combinations of droxidopa and one or more further pharmaceutically active compounds, said further compounds preferentially being selected from the group of COMT inhibiting compounds, cholinesterase inhibiting compounds, and monoamine oxidase inhibiting compounds. The invention further provides methods of treating conditions, such as orthostatic hypotension, comprising administering the combinations.

US Patent:

20080227830, Sep 18, 2008

Filed:

Mar 12, 2008

Appl. No.:

12/047035

Inventors:

Michael J. Roberts - Charlotte NC, US
Simon Pedder - Fort Mill SC, US

International Classification:

A61K 31/198
A61K 31/165
A61K 31/4412
A61K 31/44

US Classification:

514351, 514567, 514619, 514354

Abstract:

The present invention is directed to methods of treating neurally mediated hypotension. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, that can be administered to a patient for the treatment of neurally mediated hypotension.

US Patent:

20110081338, Apr 7, 2011

Filed:

Oct 5, 2010

Appl. No.:

12/898297

Inventors:

Michael J. Roberts - Charlotte NC, US
Simon Pedder - Fort Mill SC, US

International Classification:

A61K 39/395
A61K 31/517
A61K 31/573
A61K 38/16
A61P 35/00
A61P 19/02
A61P 29/00
A61P 3/00
A61P 25/28
A61P 11/06
A61P 25/16

US Classification:

4241331, 514249, 514171, 514 11, 4241421

Abstract:

The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.

US Patent:

20110082149, Apr 7, 2011

Filed:

Oct 5, 2010

Appl. No.:

12/898291

Inventors:

Michael J. Roberts - Charlotte NC, US
Simon Pedder - Fort Mill SC, US

International Classification:

A61K 31/519
A61P 35/00
A61P 29/00
A61P 17/06
A61P 9/00
A61P 9/10
A61P 11/00
A61P 37/08
A61P 37/00
A61P 19/02
A61P 1/00
A61P 27/02

US Classification:

514249

Abstract:

The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals.